Actively Recruiting
Phase 1 Study of Single Intrathecal Dose of CNTX-3001 for Adults With Intractable Moderate to Severe Chronic Low Back Pain
Led by Centrexion Therapeutics · Updated on 2026-03-23
16
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety, tolerability, plasma pharmacokinetics, and effectiveness of an investigational drug called CNTX-3001 in people with intractable chronic moderate to severe low back pain who have not responded well to other treatments. This Phase 1 first-in-human study aims to determine if CNTX-3001, a novel non-opioid small molecule, can be safely given to these participants. The study is sponsored by Centrexion Therapeutics. Participants will receive a single intrathecal injection of either CNTX-3001 or normal saline placebo via lumbar puncture. The study is randomized and triple-masked, comparing the investigational drug to placebo. The treatment is administered once, and participants are monitored closely for safety and drug levels. During the study, participants will undergo assessments for adverse events from baseline to Day 7, as well as plasma sampling up to 4 hours post-dose to measure drug concentrations and pharmacokinetics. Researchers will monitor participants pain levels, leg strength, and overall safety. The total participation period includes the treatment day and follow-up visits during the first week after dosing.
CONDITIONS
Brief Title
Safety and PK of Intrathecal CNTX-3001 for Intractable Chronic Low Back Pain
Research Team
C
Clinical Operations
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here